Aroxybutynin and Atomoxetine

Phase 3Small molecule

Aroxybutynin and Atomoxetine is one of 47 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

Obstructive Sleep ApneaPhase 3

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Asmanex

Novartis

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Farxiga

AstraZeneca

Phase 3

1 4

Foundayo

Eli Lilly

Phase 3

1 5

MS Contin

Lunesta

3 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 8

Ketalar

AAultman Health Foundation

Phase 3

2 9

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 10

Advil

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Obstructive Sleep Apnea1 trial

Continuation Protocol for Obstructive Sleep Apnea (OSA)

Enrolling by invitation·AApnimed·Phase 3·NCT06566820·1,280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aroxybutynin and Atomoxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aroxybutynin and Atomoxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aroxybutynin and Atomoxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apnimed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AApnimed

Aroxybutynin and Atomoxetine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Obstructive Sleep Apnea1 trial

References

Drug Info

Quick Facts

Related News